| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
|---|
| Outline of Final Research Achievements |
Differentiated embryonic chondrocyte expressed gene 1 (DEC1; BHLHE40/Stra13/Sharp2) and differentiated embryonic chondrocyte expressed gene 2 (DEC2; BHLHE41/Sharp1) are basic helix-loop-helix (bHLH) transcriptional factors that are involved in the regulation of cell differentiation, circadian rhythms, response to hypoxia and carcinogenesis. DEC1 is overexpressed in various tumor regions. High levels of DEC1 mRNA are also detected in an array of cancer cell lines. We reported that DEC1 has pro-apoptotic effects, whereas DEC2 has no apoptotic effect on human esophageal cancer TE10 cells. DEC2 has anti-apoptotic effects, whereas DEC1 has no apoptotic effect on human oral cancer HSC-3 cells. DEC1 and DEC2 have no apoptotic effect in TE5 and CA9-22. These different apoptotic effects of DEC1 and DEC2 may depend on the differences of cell lines and/or gene expression. However, the mechanism of DEC in tumor apoptotic pathway is poorly understood, so further studies are needed.
|
